AbbVie International — Collaboration revenues increased by 12.6% to $224.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.2%, from $209.00M to $224.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests successful international collaboration and effective monetization of shared intellectual property, while a decrease may indicate maturing partnerships or reduced market performance of jointly developed products.
This metric represents the company's proportional share of profits derived from international collaborative arrangements...
Comparable to 'equity method income' or 'collaboration revenue' reported by other large-cap pharmaceutical firms engaged in co-development or co-promotion agreements.
abbv_segment_international_collaboration_revenues| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $282.00M | $265.00M | $299.00M | $283.00M | $286.00M | $240.00M | $241.00M | $230.00M | $228.00M | $238.00M | $210.00M | $209.00M | $211.00M | $199.00M | $224.00M |
| QoQ Change | — | -6.0% | +12.8% | -5.4% | +1.1% | -16.1% | +0.4% | -4.6% | -0.9% | +4.4% | -11.8% | -0.5% | +1.0% | -5.7% | +12.6% |
| YoY Change | — | — | — | +0.4% | +7.9% | -19.7% | -14.8% | -19.6% | -5.0% | -1.2% | -8.7% | -8.3% | -11.3% | -5.2% | +7.2% |